Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1646 1674
This examiner grants 40% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18405772 | HIGH CONCENTRATION SOLUTION ANTIBODY FORMULATIONS COMPRISING ANTI-IL-23p19 ANTIBODIES | Non-Final OA | MERCK SHARP & DOHME LLC |
| 17938846 | METHODS OF TREATING NEW-ONSET PLAQUE TYPE PSORIASIS USING IL-17 ANTAGONISTS | Non-Final OA | NOVARTIS AG |
| 19187615 | BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS | Final Rejection | MOONLAKE IMMUNOTHERAPEUTICS AG |
| 19095314 | IL10RB BINDING MOLECULES AND ENCODING NUCLEIC ACIDS | Non-Final OA | Synthekine, Inc. |
| 17679675 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME | Non-Final OA | Merck Patent GmbH |
| 17743864 | Treatment of Genital Psoriasis | Non-Final OA | Eli Lilly and Company |
| 16643377 | Methods for Treating TNFa-Related Diseases | Final Rejection | Celltrion Inc. |
| 18166878 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | Non-Final OA | Janssen Biotech, Inc. |
| 18045597 | Methods of Treatment Using Anti-IL-17A/F Antibodies | Non-Final OA | UCB BIOPHARMA SRL |
| 16943947 | Methods for Monitoring Polymorphonuclear Myeloid Derived Suppressor Cells and Compositions and Methods of Treatment of Cancer | Final Rejection | The Wistar Institute of Anatomy and Biology |
| 17794245 | METHODS FOR DOSING AND TREATMENT OF FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA IN ADOPTIVE CELL THERAPY | Final Rejection | Juno Therapeutics, Inc. |
| 18270706 | PREVENTION AND TREATMENT OF STEROID-RESISTANT OR GUT GRAFT-VERSUS-HOST DISEASE (GVHD) | Non-Final OA | CIY OF HOPE |
| 17197580 | Use of ST266 to Treat Severe Systemic Inflammation and Post-Acute COVID-19 Syndrome | Final Rejection | Noveome Biotherapeutics, Inc. |
| 17406847 | MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF | Final Rejection | Bright Peak Therapeutics AG |
| 18009826 | SARS-COV-2 IMMUNODOMINANT PEPTIDES AND USES THEREOF | Non-Final OA | AHS Hospital Corp. |
| 17995895 | Compositions and Methods of Treating a Coronavirus Infection By Use of an Interferon Fusion Protein | Final Rejection | East Carolina University |
| 17939634 | METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT | Final Rejection | AVEO Pharmaceuticals, Inc. |
| 17045363 | SYNTHETIC SIGNALING CONSTRUCTS AND ITS USE | Non-Final OA | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy